Highlights Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
5.56 ^USD	+10.43%		-1.07%	-45.11%

05-09	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	MT
05-09	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	CI
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Editas Medicine and Vertex Pharmaceuticals Enter into Non-Exclusive License Agreement for Cas9	12-13	CI
Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology Annual Meeting And In A Company-Sponsored Webinar	12-11	CI
Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar	11-02	CI
Editas Medicine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/08/23	CI
Editas Medicine, Inc. and Azzur Cleanrooms on Demand, Azzur Group Company, Expand their Multi-Year Contract to Support Scaling of EDIT-301	27/07/23	CI
Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial	09/06/23	CI
Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress	11/05/23	CI
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/05/23	CI
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director	13/04/23	GL
Editas Medicine's Q4 Net Loss Widens, Revenue Falls	22/02/23	MT
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	22/02/23	CI
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	22/02/23	CI
Shoreline Biosciences, Inc. completed the acquisition of Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.	30/01/23	CI
Editas Medicine to Sell iNK Cell Franchise, Related Technologies to Shoreline Biosciences for Undisclosed Sum	19/01/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Highlights

Filters